Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

被引：89

作者：

Krishna, R. ^{[1
]}

Bergman, A. J. ^{[1
]}

Jin, B. ^{[1
]}

Fallon, M. ^{[1
]}

Cote, J. ^{[1
]}

Van Hoydonck, P. ^{[1
]}

Laethem, T. ^{[1
]}

Gendrano, I. N., III ^{[1
]}

Van Dyck, K. ^{[1
]}

Hilliard, D. ^{[1
]}

Laterza, O. ^{[1
]}

Snyder, K. ^{[1
]}

Chavez-Eng, C. ^{[1
]}

Lutz, R. ^{[1
]}

Chen, J. ^{[1
]}

Bloomfield, D. M. ^{[1
]}

De Smet, M. ^{[1
]}

Van Bortel, L. M. ^{[2
]}

Gutierrez, M. ^{[3
]}

Al-Huniti, N. ^{[4
]}

Dykstra, K. ^{[4
]}

Gottesdiener, K. M. ^{[1
]}

Wagner, J. A. ^{[1
]}

机构：

[1] Merck & Co Inc, Whitehouse Stn, Whitehouse Stn, NJ USA

[2] Ghent Univ Hosp, Drug Res Unit Ghent, B-9000 Ghent, Belgium

[3] Comprehens Phase One Inc, Miramar, FL USA

[4] Pharsight Corp, Cary, NC USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 84卷 / 06期

关键词：

D O I：

10.1038/clpt.2008.109

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

Cholesteryl ester transfer protein (CETP) is a plasma protein that catalyzes the heteroexchange of cholesteryl esters from high-density lipoprotein (HDL) and trglycerides to apolipoprotein B-containing lipoproteins, especially very low-density lipoproteins (LDL-C).(1,2)

引用

页码：679 / 683

页数：5

共 25 条

[1]

Effects of torcetrapib in patients at high risk for coronary events [J].

Barter, Philip J. ;

Caulfield, Mark ;

Eriksson, Mats ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Mosca, Lori ;

Tardif, Jean-Claude ;

Waters, David D. ;

Shear, Charles L. ;

Revkin, James H. ;

Buhr, Kevin A. ;

Fisher, Marian R. ;

Tall, Alan R. ;

Brewer, Bryan .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122

[2]

BERGMAN A, 2007, AM ASS PHARM SCI ANN

[3]

BLOOMFIELD DM, 2007, 16 INT S DRUGS AFF L

[4]

Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action [J].

Clark, RW ;

Ruggeri, RB ;

Cunningham, D ;

Bamberger, MJ .

JOURNAL OF LIPID RESEARCH, 2006, 47 (03) :537-552

[5]

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib [J].

Clark, RW ;

Sutfin, TA ;

Ruggeri, RB ;

Willauer, AT ;

Sugarman, ED ;

Magnus-Aryitey, G ;

Cosgrove, PG ;

Sand, TM ;

Wester, RT ;

Williams, JA ;

Perlman, ME ;

Bamberger, MJ .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (03) :490-497

[6]

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels [J].

Davidson, Michael H. ;

McKenney, James M. ;

Shear, Charles L. ;

Revkin, James H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (09) :1774-1781

[7]

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study [J].

de Grooth, GJ ;

Kuivenhoven, JA ;

Stalenhoef, AFH ;

de Graaf, J ;

Zwinderman, AH ;

Posma, JL ;

van Tol, A ;

Kastelein, JJP .

CIRCULATION, 2002, 105 (18) :2159-2165

[8]

A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology [J].

Eveland, Suzanne S. ;

Milot, Denise P. ;

Guo, Qiu ;

Chen, Ying ;

Hyland, Sheryl A. ;

Peterson, Laurence B. ;

Jezequel-Sur, Sylvie ;

O'Donnell, Gregory T. ;

Zuck, Paul D. ;

Ferrer, Marc ;

Strulovici, Berta ;

Wagner, John A. ;

Tanaka, Wesley K. ;

Hilliard, Deborah A. ;

Laterza, Omar ;

Wright, Samuel D. ;

Sparrow, Carl P. ;

Anderson, Matt S. .

ANALYTICAL BIOCHEMISTRY, 2007, 368 (02) :239-249

[9]

FORREST MJ, 2007, AM HEART ASS M

[10]

Gibaldi M, 1982, Pharmacokinetics, V15

← 1 2 3 →